tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

CRISM Therapeutics Earns MHRA Innovation Passport

CRISM Therapeutics Earns MHRA Innovation Passport

Amur Minerals (GB:CRTX) has released an update.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

CRISM Therapeutics Corporation has been awarded an Innovation Passport for their ChemoSeed product for high grade gliomas by the UK’s MHRA, expediting the treatment’s development and access. Additionally, the company has received a £25,000 grant from SPARK The Midlands to further support their innovative cancer treatment technology. The CEO, Andrew Webb, highlighted these recognitions as significant milestones and endorsements for the potential of ChemoSeed to transform brain tumour treatments.

For further insights into GB:CRTX stock, check out TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1